Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

11.18 +0.23 (+2.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,330,154
Open 11.04
Bid (Size) 10.99 (2)
Ask (Size) 11.17 (1)
Prev. Close 10.95
Today's Range 10.93 - 11.25
52wk Range 3.060 - 11.27
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily

Performance

YTD
+145.71%
+145.71%
1 Month
+18.94%
+18.94%
3 Month
+70.95%
+70.95%
6 Month
+147.35%
+147.35%
1 Year
+207.99%
+207.99%

More News

Read More
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Via Benzinga
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
Via Benzinga
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
Via Benzinga
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
Via Benzinga
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Recap: ADMA Biologics Q4 Earnings
Via Benzinga
Earnings Preview For ADMA Biologics
Via Benzinga
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Chart Of The Day: ADMA Biologics - Hitting New Highs
Via Talk Markets
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces CFO Transition
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
From ADMA Biologics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.